COVID-19, the great unequalizer
Johnson & Johnson announced Friday that it has started testing its vaccine on adolescents.
The single-shot vaccine will first be tested on a small number of 16 and 17-year-olds as part of an ongoing study of the vaccine that began last September, the company said.
After initial data from the older teens is available, the trial will be gradually expanded to a larger group of younger adolescents between ages 12 and 15.
The vaccine, developed by Johnson & Johnson's subsidiary Janssen in the Netherlands, is already being administered in the US and was given EU approval on March 11.
The Twitter handle of Russian vaccine